Abstract
Background: Propofol is a sedative agent that at clinical concentrations acts by allosterically activating or potentiating the γ-aminobutyric acid type A (GABAA) receptor. Mutational, modeling, and photolabeling studies with propofol and its analogues have identified potential interaction sites in the transmembrane domain of the receptor. At the "+" of the β subunit, in the β-α interface, meta-azipropofol labels the M286 residue in the third transmembrane domain. Substitution of this residue with tryptophan results in loss of potentiation by propofol. At the "-" side of the β subunit, in the α-β interface (or β-β interface, in the case of homomeric β receptors), ortho-propofol diazirine labels the H267 residue in the second transmembrane domain. Structural modeling indicates that the β(H267) residue lines a cavity that docks propofol with favorable interaction energy.
Method: We used two-electrode voltage clamp to determine the functional effects of mutations to the "+" and "-" sides of the β subunit on activation of the α1β3 GABAA receptor by propofol.
Results: We found that while the individual mutations had a small effect, the combination of the M286W mutation with tryptophan mutations of selected residues at the α-β interface leads to strong reduction in gating efficacy for propofol.
Conclusion: We conclude that α1β3 GABAA receptors can be activated by propofol interactions with the β-β, α-β, and β-α interfaces, where distinct, non-equivalent regions control channel gating. Any interface can mediate activation, hence substitutions at all interfaces are required for loss of activation by propofol.
Keywords: Activation, binding site, GABAA receptor, mutation, propofol, structure.
Current Neuropharmacology
Title:Multiple Non-Equivalent Interfaces Mediate Direct Activation of GABAA Receptors by Propofol
Volume: 14 Issue: 7
Author(s): Megan M. Eaton, Allison L. Germann, Ruby Arora, Lily Q. Cao, Xiaoyi Gao, Daniel J. Shin, Albert Wu, David C. Chiara, Jonathan B. Cohen, Joe Henry Steinbach, Alex S. Evers and Gustav Akk
Affiliation:
Keywords: Activation, binding site, GABAA receptor, mutation, propofol, structure.
Abstract: Background: Propofol is a sedative agent that at clinical concentrations acts by allosterically activating or potentiating the γ-aminobutyric acid type A (GABAA) receptor. Mutational, modeling, and photolabeling studies with propofol and its analogues have identified potential interaction sites in the transmembrane domain of the receptor. At the "+" of the β subunit, in the β-α interface, meta-azipropofol labels the M286 residue in the third transmembrane domain. Substitution of this residue with tryptophan results in loss of potentiation by propofol. At the "-" side of the β subunit, in the α-β interface (or β-β interface, in the case of homomeric β receptors), ortho-propofol diazirine labels the H267 residue in the second transmembrane domain. Structural modeling indicates that the β(H267) residue lines a cavity that docks propofol with favorable interaction energy.
Method: We used two-electrode voltage clamp to determine the functional effects of mutations to the "+" and "-" sides of the β subunit on activation of the α1β3 GABAA receptor by propofol.
Results: We found that while the individual mutations had a small effect, the combination of the M286W mutation with tryptophan mutations of selected residues at the α-β interface leads to strong reduction in gating efficacy for propofol.
Conclusion: We conclude that α1β3 GABAA receptors can be activated by propofol interactions with the β-β, α-β, and β-α interfaces, where distinct, non-equivalent regions control channel gating. Any interface can mediate activation, hence substitutions at all interfaces are required for loss of activation by propofol.
Export Options
About this article
Cite this article as:
Eaton M. Megan, Germann L. Allison, Arora Ruby, Cao Q. Lily, Gao Xiaoyi, Shin J. Daniel, Wu Albert, Chiara C. David, Cohen B. Jonathan, Steinbach Henry Joe, Evers S. Alex and Akk Gustav, Multiple Non-Equivalent Interfaces Mediate Direct Activation of GABAA Receptors by Propofol, Current Neuropharmacology 2016; 14 (7) . https://dx.doi.org/10.2174/1570159X14666160202121319
DOI https://dx.doi.org/10.2174/1570159X14666160202121319 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Enhancing Neuropharmacology with Home Cage Monitoring, Advanced Delivery and Stimulation Technologies, and Artificial Intelligence
Home cage monitoring (HCM) technologies have revolutionized neuropharmacological research by enabling continuous, non-invasive observation of rodents in their natural environments. Complementary advancements such as 24/7 continuous drug delivery systems (e.g., implantable pumps) and wireless neurostimulation methods—including optogenetics—offer precise methods for modulating neural activity and administering pharmacological agents without disrupting the ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Topics in Medicinal Chemistry The Role of Circadian Rhythms, Light and Melatonin in SAD and Nonseasonal Affective and Anxiety Disorders
Current Psychiatry Reviews Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells
Current Neurovascular Research Cyclooxygenase-2 (COX-2) Mediates Arsenite Inhibition of UVB-Induced Cellular Apoptosis in Mouse Epidermal Cl41 Cells
Current Cancer Drug Targets Applications and Modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid (Tic) in Peptides and Peptidomimetics Design and Discovery
Current Protein & Peptide Science Treatment of Organophosphate Intoxication Using Cholinesterase Reactivators:Facts and Fiction
Mini-Reviews in Medicinal Chemistry Structural and Physicochemical Profiling of Morphine and Related Compounds of Therapeutic Interest
Mini-Reviews in Medicinal Chemistry Granulomatous Lung Disease. Disease for Pulmomologists: Diagnosis and Treatment
Current Respiratory Medicine Reviews Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Involvement of microRNA-146a in the Inflammatory Response of S tatus Epilepticus Rats
CNS & Neurological Disorders - Drug Targets Recent Advances in the Applications of the Intramolecular Suzuki Cross-coupling Reaction in Cyclization and Heterocyclization: An Update
Current Organic Chemistry Recreational Use, Analysis and Toxicity of Tryptamines
Current Neuropharmacology Thirty Years of Dutch Drugs and Driving Research: Strengths and Limitations of the On-The-Road Highway Driving Test and Future Challenges
Current Psychopharmacology Potential Efficacy of Some African Plants in Benign Prostatic Hyperplasia and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Melanocortin Receptor Type 3 as a Potential Target for Anti-Inflammatory Therapy
Current Drug Targets - Inflammation & Allergy Comparison of Midwifery Consultation and Fluoxetine on IVF Outcomes in Depressed Infertile Women: A Clinical Trial Research Study
Current Women`s Health Reviews